21 Firmen mit Ergebnissen für "late"

University of Zurich

https://www.campus-schlieren.uzh.ch/en.html  

8952 Schlieren, Wagistrasse 12

The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.

University of Zurich

Wagistrasse 12

8952 Schlieren

919 Ergebnisse für "late" unter University of Zurich

CfP Late Soviet Village EN

... CfP Late Soviet Village EN       History Department East European History             Late Soviet ... they are crucial for understanding the late Soviet Union. The current debate on the texture of late ... CfP Late Soviet Village EN ... CfP Late Soviet Village EN       History Department East European History             Late Soviet ... CfP Late Soviet Village EN ...

UZH - SNSF Professorship Ekaterina Emeliantseva Koller - Late Sovie...

... Late Soviet Village © Mark Shteinbok project homepage The project studies ambivalences of late ... reproducing the traditional narrative of decline, it proposes a new conceptualisation of the late Soviet ... UZH - SNSF Professorship Ekaterina Emeliantseva Koller - Late Soviet Village ... UZH - SNSF Professorship Ekaterina Emeliantseva Koller - Late Soviet Village Home Hauptnavigation ... UZH - SNSF Professorship Ekaterina Emeliantseva Koller - Late Soviet Village ...

Mehr Ergebnisse

ETH Entrepreneurship

https://ethz.ch/en/industry/entrepreneurship.html  

8952 Schlieren, Wagistrasse 18


 entrepreneurship@ethz.ch

Excellence in entrepreneurship at ETH Zurich is driven by world-​class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions. 

ETH Entrepreneurship

Wagistrasse 18

8952 Schlieren

537 Ergebnisse für "late" unter ETH Entrepreneurship

Comments on: Bork, Late Gothic Architecture

... Comments on: Bork, Late Gothic Architecture Comments on: Bork, Late Gothic Architecture your books ... Comments on: Bork, Late Gothic Architecture ... https://xenotheka.delbeke.arch.ethz.ch/bork- late-gothic-architecture/feed/ ... Comments on: Bork, Late Gothic Architecture ...

Late Gothic Constructions in Müstair and Meran - Research Collection

... Late Gothic Constructions in Müstair and Meran - Research Collection ... Late Gothic Constructions in Müstair and Meran - Research Collection Header Upper Right Menu Log in ... Late Gothic Constructions in Müstair and Meran - Research Collection ...

Mehr Ergebnisse

Somagenetix

https://www.wysszurich.ch/projects/somagenetix  

8952 Schlieren, Wagistrasse 23

Gene therapy solutions for patients with severe inherited diseases.

Somagenetix

Wagistrasse 23

8952 Schlieren

1922 Ergebnisse für "late" unter Somagenetix

Ad fontes: Resources / Latin in the Sources / The Late Middle Ages ...

... Ad fontes: Resources / Latin in the Sources / The Late Middle Ages and Modernity: Literature ... Ad fontes: Resources / Latin in the Sources / The Late Middle Ages and Modernity: Literature All ... Ad fontes: Resources / Latin in the Sources / The Late Middle Ages and Modernity: Literature ...

Ad fontes: Resources / Analyzing Sources / The Papal Curia in the L...

... Ad fontes: Resources / Analyzing Sources / The Papal Curia in the Late Middle Ages: Organizational ... Ad fontes: Resources / Analyzing Sources / The Papal Curia in the Late Middle Ages: Organizational ... Ad fontes: Resources / Analyzing Sources / The Papal Curia in the Late Middle Ages: Organizational ...

Mehr Ergebnisse

Bio-Technopark Schlieren-Zürich

http://www.bio-technopark.ch/  

8952 Schlieren, Wagistrasse 23

 +41 76 336 99 44
 mario.jenni@bio-technopark.ch

The Bio-Technopark offers professional support for life science start-ups in the setting up and expansion of business activities and promotes interaction between start-ups, academia and industry. A nationally and internationally respected science park has grown up at Schlieren. Through stringent selection, coaching and support, more than 30 successful start-up companies with 750 employees are located here. Eight have been acquired by large corporates, but are still active in the park. Together with 20 institutes and clinics from the University and University Hospital Zurich, an innovative mix of very young and well-established companies and academic research groups has emerged.

Bio-Technopark Schlieren-Zürich

Wagistrasse 23

8952 Schlieren

13 Ergebnisse für "late" unter Bio-Technopark Schlieren-Zürich

Allergan and Molecular Partners Present Late-Breaking Data from Pha...

... News Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of ... the maintenance of visual gains comparable to monthly ranibizumab. These data were presented as a late ... Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational ... https://www.bio-technopark.ch/en/news-en/allergan-and-molecular-partners-present- late-breaking-data ... Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational ...

Neurimmune Welcomes Biogen’s News on Clinical Benefit of Aducanumab...

... clinical benefit.” For the first time, large late-stage clinical study results showed that removal of ... collaborations with selected industry partners for late-stage clinical development and commercialization, with ... clinical benefit.” For the first time, large late-stage clinical study results showed that removal of ... collaborations with selected industry partners for late-stage clinical development and commercialization, with ...

Mehr Ergebnisse

Molecular Partners AG

http://www.molecularpartners.com  

8952 Schlieren, Wagistrasse 14

 +41 44 755 77 00

Molecular Partners AG is a clinical-stage biopharmaceutical company, located in Schlieren, Switzerland, that is developing a new class of therapies known as DARPin® therapies.

Molecular Partners AG

Wagistrasse 14

8952 Schlieren

6 Ergebnisse für "late" unter Molecular Partners AG

Allergan and Molecular Partners Present Late-Breaking Data from Pha...

... Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational ... comparable to monthly ranibizumab.  These data were presented as a late-breaking oral presentation during ... Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational ... -partners-present- late-breaking-data-phase ... Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational ...

Late-Stage Data from Abicipar in Age-Related Macular Degeneration t...

... News Release Details News Release Details Late-Stage Data from Abicipar in Age-Related Macular ... follows: Retina Subspecialty Day, Late Breaking – RET 11 – Section VIII: Late Breaking Developments, Part ... Late-Stage Data from Abicipar in Age-Related Macular Degeneration to be Showcased at American ... https://investors.molecularpartners.com/news-releases/news-release-details/ late-stage-data-abicipar ... Late-Stage Data from Abicipar in Age-Related Macular Degeneration to be Showcased at American ...

Mehr Ergebnisse

InSphero AG

http://www.insphero.com  

8952 Schlieren, Wagistrasse 27

 +41 44 515049-0
 info@insphero.com

InSphero is a leading supplier of organotypic, biological in vitro 3D microtissues for highly predictive drug testing. The company currently counts all of the top ten global pharmaceutical and cosmetics companies as customers and is helping them to implement its patented microtissue technology in their development work-flow.

InSphero AG

Wagistrasse 27

8952 Schlieren

20 Ergebnisse für "late" unter InSphero AG

Insphero

... session " Late-Breaking Research: Tumor Biology 1 ( Late-Breaking Poster Session, LBPO.TB01)", Monday, April ... session " Late-Breaking Research: Tumor Biology 1 ( Late-Breaking Poster Session, LBPO.TB01)", Monday, April ...

... specificity Minimize risks late-stage market withdrawal Rely on ISO 9001:2015 quality-controlled microtissues ... LDH-Release Assay that Enables “Real-Time” Sampling from Individual 3D Microtissues Session: Late ... specificity Minimize risks late-stage market withdrawal Rely on ISO 9001:2015 quality-controlled microtissues ... Luminescent LDH-Release Assay that Enables “Real-Time” Sampling from Individual 3D Microtissues Session: Late ...

Mehr Ergebnisse

NovaGo Therapeutics AG

http://www.novagotherapeutics.com  

8952 Schlieren, Wagistrasse 27


 info@novagotherapeutics.com

NovaGo Therapeutics is a biotech start-up company dedicated to the development of human antibody therapeutics that promote nerve repair and regeneration in the treatment of cerebral stroke and spinal cord injury. NovaGo is developing human antibody therapeutics against Nogo-A. Nogo-A is the most potent inhibitor of nerve fiber regeneration. Anti-NogoA treatment promotes recovery of function in several animal models of stroke. Novago Therapeutics' anti-NogoA treatment represents a novel, regenerative approach for stroke. Recovery of function in stroke and other neurological disorders will be a clinical breakthrough and have a major economic impact on health care.

NovaGo Therapeutics AG

Wagistrasse 27

8952 Schlieren

2 Ergebnisse für "late" unter NovaGo Therapeutics AG

Existing Partnerships | NovaGo Therapeutics

... aducanumab, is currently being tested in late-stage clinical trials for the treatment of Alzheimer‘s disease ... aducanumab, is currently being tested in late-stage clinical trials for the treatment of Alzheimer‘s disease ...

Management | NovaGo Therapeutics

... delivery of the late-stage clinical development program of ocrelizumab for multiple sclerosis. Eduardo has ... delivery of the late-stage clinical development program of ocrelizumab for multiple sclerosis. Eduardo has ...

Roche Glycart AG

https://www.roche.ch/en/sites/schlieren  

8952 Schlieren, Wagistrasse 10

 +41 43 215 10 00

The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.

Roche Glycart AG

Wagistrasse 10

8952 Schlieren

103 Ergebnisse für "late" unter Roche Glycart AG

Roche | Roche's Pharma Day 2019

... Afternoon sessions (breakouts) Late stage pipeline Ophthalmology Atul Dandekar Ophthalmology Franchise Head ... Diseases & Ophthalmology, Global Product Strategy Late stage pipeline Ophthalmology Atul Dandekar ...

Heart Failure

... patients, caregivers and healthcare systems. A late diagnosis of heart failure in the UK is common and 80 ... the cycle of late diagnosis in the UK and opportunities to tackle this in our latest report published ... failure places great stress on patients, caregivers and healthcare systems. A late diagnosis of heart ... Key Areas 'Breaking the cycle: Tackling late heart failure diagnosis in the UK' 2022 report Learn more ...

Mehr Ergebnisse

University Hospital Zurich​, Research and Education Office

https://www.usz.ch/forschung/Seiten/default.aspx  

8091 Zürich, Rämistrasse 100

The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.

University Hospital Zurich​, Research and Education Office

Rämistrasse 100

8091 Zürich

100 Ergebnisse für "late" unter University Hospital Zurich​, Research and Education Office

Slide S VII 17

... ". Decreased fetal movement in late pregnancy. Now distinct delayed motor development. Muscle biopsy of the ... ". Decreased fetal movement in late pregnancy. Now distinct delayed motor development. Muscle biopsy of the ...

Microsoft PowerPoint - Freystätter_Testosteron bei Männern 70+_27-1...

... 3 / Symptome eines Testosteron Mangels Wu et al Identification of Late-Onset Hypogonadism in Middle ... , Erektionsschwäche, ↓Libido + T < 11 nmol/l = = Late-onset hypogonadism / The Testosterone Trials 7 double-blind ... 3 / Symptome eines Testosteron Mangels Wu et al Identification of Late-Onset Hypogonadism in Middle ... , Erektionsschwäche, ↓Libido + T < 11 nmol/l = = Late-onset hypogonadism / The Testosterone Trials 7 double-blind ...

Mehr Ergebnisse

CSL Vifor

https://www.csl.com/we-are-csl/our-businesses-and-products/csl-vifor  

8952 Schlieren, Zürcherstrasse 39D

 +41 58 851 80 00

Pioneer in iron-based therapies, CSL Vifor is a global leader in iron deficiency and iron deficiency anaemia therapies, with a history dating back to 1872, when pharmacist Caspar Friedrich Hausmann opened a pharmacy in St. Gallen, Switzerland. Since then, we have proven our ability to identify and serve therapeutic areas and patients with significant unmet medical need. Building on our heritage and expertise in iron deficiency therapy, and together with our joint company Vifor Fresenius Medical Care Renal Pharma, today we have a strong and rapidly growing presence in nephrology, and we are committed to launching the next generation of therapies to truly address the full spectrum of kidney disease.

CSL Vifor

Zürcherstrasse 39D

8952 Schlieren

18 Ergebnisse für "late" unter CSL Vifor

CSL Annual Report 2022 – Page 3

... up playing sports and later moved on to weightlifting and bowling. In his late 30s, however, he was ... . In his late 30s, however, he was robbed of his mobility and left in severe pain by chronic ...

CSL Annual Report 2022 – Page 22

... anti-factor XIIa monoclonal antibody in late stage development has the potential to provide patients ... attacks for patients, garadacimab – our anti-factor XIIa monoclonal antibody in late stage development has ...

Mehr Ergebnisse

Mehr Firmen

Nach oben